Our website does not fully support your browser.

We've detected that you are using an older version of Internet Explorer. Your commerce experience may be limited. Please update your browser to Internet Explorer 11 or above.

Promega's Cookie Policy

We use cookies and similar technologies to make our website work, run analytics, improve our website, and show you personalized content and advertising. Some of these cookies are essential for our website to work. For others, we won’t set them unless you accept them. To find out more about cookies and how to manage cookies, read our Cookie Policy.

Bioluminescent Metabolite Assays Enable Easy Measurement of Changes in Tumor Biology

Part # PS301

Abstract

Michael P. Valley, Donna Leippe, Mary Sobol, Natasha Karassina, Sarah Duellman, James J. Cali, and Jolanta Vidugiriene
Promega Corporation, 2800 Woods Hollow Rd, Madison, WI 53711
Abstract # 4026
Tumor cells rely on metabolic reprogramming to meet their increased demands for energy and biomass. Such reprogramming is exemplified by increased rates of glucose uptake, greater utilization of glycolysis, and a reliance on glutaminolysis. We have developed a suite of bioluminescent assays that can monitor metabolites in all of these important pathways.

Printed in USA.